AstraZeneca hits sales of more than €225m from Covid-19 jabs

Bosses said sales of some of the company’s other drugs had been affected by the global pandemic, as other medical conditions went untreated, but overall sales remained strong.

AstraZeneca has enjoyed a boost in sales from its Covid-19 vaccine (Nick Potts/PA)

AstraZeneca has revealed it banked revenues of $275m US dollars (€227m) in the first three months of the year from sales of its Covid-19 vaccine, delivering 68 million doses worldwide.

The pharmaceutical, which is not making a profit from the vaccine, added that, of those sales, $224m (€185m) worth were in Europe, $43m (€36m) in emerging markets and $8m (€6.6m) in the rest of the world.